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Objectives 
 
 Distinguish between symptomatic UTI and asymptomatic 
bacteriuria in older adults, and apply this distinction to 
reduce unnecessary antibiotic use. 
 Estimate risk of antibiotic resistant pathogens in pneumonia 
in nursing home residents and identify prescribing practices 
for pneumonia that may contribute to unnecessary antibiotic 
exposure. 
 Describe measures to prevent outbreaks and reduce risk of 
C. difficile infection in LCTFs. 
 Discuss criteria to reduce the risk of antibiotic associated 
adverse events in elders. 
 
 
 
 
 
 
 

American Geriatrics Society Identifies 
Five Things That Healthcare Providers 
and Patients Should Question 
#4.  Do not use antimicrobials to treat 
bacteriuria in older adults unless specific 
urinary tract symptoms are present. 
 
   -AGS Choosing Wisely Workgroup 
 
J Am Geriatr Soc  61:622–631, 2013. 
  
Prevalence (%) 
 
Population 
 
Women 
 
Men 
 
Community 
 
9-33 
 
2.4-13 
 
Institutionalized 
 
 
17-55 
 
 
15-37 
  Yoshikawa, 1996 
 
 
Prevalence of Asymptomatic 
Bacteriuria in Older Populations 
Reasons to avoid antibiotic treatment of 
asymptomatic bacteriuria 
 Doesn’t reduce mortality 
 NNH=31 
 Increased antibiotic resistance 
  
1Nicolle et al. Am J Med. 1987. 
Author Subjects Intervention Outcome 
Nicolle et al, 
NEJM 1983 
36 Men  
> 80 yr 
NH residents 
Randomized to abx 
vs none. Duration 2 
years 
No difference in:  
Mortality 
Infectious morbidity 
Nicolle et al, Am 
J Med 1987 
50 women 
83 yr 
NH residents 
Randomized to abx 
vs none 
Duration 1 year 
No difference in: 
Mortality 
GU morbidity 
Increased AE and 
resistance in treated 
group 
Abrutyn et al, 
Ann Intern Med 
1994 
358 women, 82 yr 
Apartment and NH 
Randomized to abx 
vs none 
Duration 8 years 
No survival benefit 
in treatment group 
Ouslander et al, 
Ann Intern Med 
1995 
71 women and men 
85 yr 
NH 
Randomized to abx 
vs placebo 
4 weeks 
No difference in 
chronic urinary inc 
symptoms 
Prospective randomized studies of treatment of asymptomatic bacteriuria 
Juthani-Mehta M. Clin Geriatr Med, 2007 
Clinical symptoms of UTI 
 Frequency 
 Urgency 
 Dysuria 
 New incontinence 
 CVA or suprapubic tenderness 
Altered clinical presentation of infection in 
older persons 
 Blunted fever response (1/3 without fever) 
 Mental status changes (acute) 
 Anorexia, malaise, weakness (new) 
 Falls (acute) 
 Incontinence (new) 
 Functional decline (change) 
Clinical features in NH residents 
attributed to “suspected UTI” 
 Prospective cohort study in women and men 
 5 Connecticut nursing homes 
 Clinically “suspected UTI” 
 Staff responses (symptoms) 
 Urinalysis/urine culture 
 Multivariable regression model 
 
Juthani-Mehta M et al. J Am Geria Soc, 2009. 
Clinical features in NH residents 
attributed to “suspected UTI” 
Juthani-Mehta M et al. J Am Geria Soc, 2009. 
Change in mental status 156 (39.1%) 
Change in behavior  76 (19.0%) 
Change in character of urine  62 (15.5%) 
Fever or chills  51 (12.8%) 
Change in gait or fall  35 (8.8%) 
Dysuria  31 (7.8%) 
Change in voiding pattern  28 (7.0%) 
Flank pain  23 (5.8%) 
Patient or family request  15 (3.8%) 
Change in functional status  10 (2.5%) 
Malaise    5 (1.3%) 
Clinical features in NH residents 
attributed to “suspected UTI” 
 399 “suspected UTI” episodes 
 240/551 subjects with at least one “suspected 
UTI” 
 Majority had negative UA (<10 WBC, <105 
cfu)  
 252/399 (63%)  
 Absence of dysuria identified subjects at low 
risk for abnormal UA 
 
Clinical features in NH residents 
attributed to “suspected UTI” 
 Conclusions 
 Staff are indiscriminant in diagnosing UTI when 
clinical deterioration is identified in NH residents. 
 A wide spectrum of nonspecific clinical symptoms 
are misinterpreted as UTI. 
 Alternate diagnoses are likely overlooked. 
Juthani-Mehta M et al. J Am Geria Soc, 2009. 
Nicolle L. J Am Geria Soc, 2009. 
 
Minimum criteria for initiation of 
empiric antibiotics for UTI in LTCF 
 UTI with no catheter 
 Acute dysuria or 
 Fever and one GU symptom 
 New urgency, frequency, suprapubic pain, gross hematuria, CVA 
tenderness or urinary incontinence 
 UTI with catheter 
 One symptom of: 
 Fever  
 CVA tenderness 
 Rigors 
 Delirium  
 
 
Loeb M et al. Infect Control Hosp Epidemiol, 2001 
Multifaceted intervention to reduce antimicrobial use for 
“suspected UTI” in LTCF 
Loeb M et al. BMJ. 
 2005. 
 
Multifaceted intervention to reduce antimicrobial use for 
“suspected UTI” in LTCF 
Loeb M et al. BMJ. 2005. 
Summary: UTI overdiagnosis and 
overtreatment 
 UTI incorrectly diagnosed in 40% of 
hospitalized older adults1 
 “UTIs” account for 30-56% of antibiotic 
scripts written in nursing homes2 
 Adverse outcomes of overtreatment 
 Emerging antibiotic resistance 
 Increased prevalence of health-care associated 
C. difficile  infections 
 1Woodford HJ et al. J Am Geriatr Soc. 2009 
2Loeb et al. BMC Health Services Research. 2002 
 
Case 2 
--83 year old NH 
resident with 
dementia. 
 
--2 day history of 
fever, lethargy and 
recent fall in 
room. 
 
--IPOST: IV 
antibiotics 
acceptable. May 
transfer to 
improve comfort. 
 
--VS: 97.7-16-76-
105/72. O2 sat 
92% RA. 
 
IDSA/ATS guideline recommendations for 
treatment of CAP 
4. Use severity-of-illness scores: 
CURB-65 criteria  
(confusion, uremia, respiratory rate, low blood pressure, age >65 years) 
  
or prognostic models:  
Pneumonia Severity Index (PSI) 
 
to identify patients with CAP who may be candidates for outpatient 
treatment. (Strong recommendation; level I evidence.) 
 
Mandell et al. Clin Infect Dis. 2007;44:S27-72. 
Criteria for severe community-acquired pneumonia. 
Mandell L A et al. Clin Infect Dis. 2007;44:S27-S72 
IDSA/ATS guideline recommendations for 
treatment of CAP 
16. Presence of comorbidities 
 chronic heart, lung, liver, renal disease, diabetes mellitus; 
 immunosuppressing conditions or use of immunosuppressing drugs; 
 use of antimicrobials within the previous 3 months 
 other risks for drug resistant infection then treat with: 
  
A. Respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin)  
 
B. β-lactam plus a macrolide  
 -High-dose amoxicillin [e.g., 1 g 3 times daily] or amoxicillin-
 clavulanate [2 g 2 times daily] or 
 -Ceftriaxone, cefpodoxime, and cefuroxime [500 mg 2 times daily]; 
 -Doxycycline [level II evidence] is an alternative to the macrolide. 
 
Mandell et al. Clin Infect Dis. 2007;44:S27-72. 
 
Health care-associated pneumonia 
(HCAP) risk factors 
 Hospitalization for more than 2 days in an 
acute care hospital in the last 90 days 
 Residence in a skilled nursing facility 
 Recent IV antibiotic therapy, chemotherapy, 
or wound care in the last 30 days 
 Attending a hospital or hemodialysis clinic 
 Immunosuppression 
ATS,IDSA. Guidelines for the management of adults with hospital-acquired, ventilator-associated   
and healthcare-associated pneumonia. Am J Respir Crit Care Med, 2005. 
Antibiotic Dosage 
Antipseudomonal cephalosporin 
  Cefepime 1–2 g every 8–12 h 
  Ceftazidime 2 g every 8 h 
Carbepenems 
  Imipenem 500 mg every 6 h or 1 g every 8 h 
  Meropenem 1 g every 8 h 
β-Lactam/β-lactamase inhibitor 
  Piperacillin–tazobactam 4.5 g every 6 h 
Aminoglycosides 
  Gentamicin 7 mg/kg per d† 
  Tobramycin 7 mg/kg per d† 
  Amikacin 20 mg/kg per d† 
Antipseudomonal quinolones 
  Levofloxacin 750 mg every d 
  Ciprofloxacin 400 mg every 8 h 
Vancomycin 15 mg/kg every 12 h‡ 
Linezolid 600 mg every 12 h 
Antibiotics for empiric therapy of healthcare-associated 
pneumonia in patients with risk factors for multidrug-resistant 
pathogens 
American Journal of Respiratory and Critical Care Medicine, Vol. 171, No. 4 (2005), pp. 388-416.  
doi: 10.1164/rccm.200405-644ST  
 
Chest. 2005;128(6):3854-3862. doi:10.1378/chest.128.6.3854 
Mean mortality rate is patients with pneumonia 
Microbiology of pneumonia 
Pathogen, % CAP HCAP HAP VAP 
S aureus 25.5 46.7 47.1 42.5 
MRSA 8.9 26.5 22.9 14.6 
S pneumoniae 16.6 5.5 3.1 5.8 
Pseudomonas 17.1 25.3 L18.4 21.2 
Chest. 2005;128(6):3854-3862.  
 
JAMA. 2006;295(21):2503-2510. doi:10.1001/jama.295.21.2503 
 
 
From: Effect of a Clinical Pathway to Reduce Hospitalizations in Nursing Home 
Residents With Pneumonia:  A Randomized Controlled Trial 
From: Effect of a Clinical Pathway to Reduce Hospitalizations in Nursing Home 
Residents With Pneumonia:  A Randomized Controlled Trial 
JAMA. 2006;295(21):2503-2510. doi:10.1001/jama.295.21.2503 
 
Summary: Nursing home acquired pneumonia 
may be treated without hospitalization 
according to a clinical pathway. 
 Broad-spectrum antibiotic therapy  
 Hospitalization within 90 days 
 Recent antibiotic therapy within the last 30 days 
 Severity of pneumonia 
 Immunosuppression 
 Poor functional status 
 Appropriate monotherapy 
 Not seriously ill 
 No risk factors 
Case 3 
--90 year old 
NH resident 
with dementia 
complicated by 
behavior 
changes on 3rd 
course of 
quinolone for 
“UTI” 
 
--Watery 
diarrhea, 
anorexia and 
recurrent fever 
 
--VS 100.7-30-
120-88/60. 
C. difficile in LTCFs 
 Prevalence 14.7% 
 Incidence 0.2-2.6 per 1000 resident days 
 Major risk for acquisition 
 Preceding antibiotic use 
 Functional disability 
 Gastrostomy feeding tube 
 Acid suppressant medications 
Simor AE. J Am Geria Soc 58:1556-1564, 2010. 
C. difficile clinical features and 
complications 
 Onset during or within 8 weeks of antibiotics 
 Watery diarrhea, abdominal cramps, fever 
 Fulminant pseudomembranous colitis may be 
life-threatening. 
 15-35% recurrence rate within 2 months 
 Relapse (same strain) 
 Recurrence (new strain) 
C. difficile diagnosis and treatment 
 Test for C. diff  toxin only on diarrheal stool 
 Do not test for cure 
 Discontinue inciting antimicrobial agent as soon as possible 
 Avoid use of antiperistaltic agents 
 Metronidazole is the drug of choice for initial episode of mild-to –
moderate CDI.  
 Metronidazole 500 mg TID for 10-14 days (mild, moderate disease) 
 Vancomycin 500 mg QID with or without IV metronidazole 500 mg q 8 hrs 
(severe, complicated CDI) 
 Same regimen as for initial episode for first recurrence  
 Do not use metronidazole beyond first recurrence or for long-term chronic 
therapy 
 Vancomycin taper or pulse regimen (Second or later recurrence ) 
 SHEA-IDSA guideline. Infect Control Hosp Epidemiol 2010: 31: 431-455. 
Measures to reduce Rick of C. difficile 
acquisition and transmission in LTCFs 
 Surveillance 
 Test for toxin only on diarrheal specimens 
 Test should not be performed to identify asymptomatic carriers 
 Barrier precautions 
 Private room/commode/dedicated patient care equipment 
 Hand hygiene with soap and water after glove removal 
 Environmental cleaning/disinfection 
 Clean with diluted hypochlorite solution 
 Antimicrobial use and other measures 
 Antibiotic stewardship programs 
CDI and interventions to improve antibiotic 
prescribing 
 Climo et al, Ann Intern Med, 1998. 
 Restriction of clindamycin in hospital 
 11.5 CDI cases/month vs. 3.33 cases/month P < .001 
 Incidence of CDI was increasing by 2.9 cases per quarter 
before restriction protocol. 
 
 
Davy P et al. Cochran Database Syst Rev 2005.  
CDI and interventions to improve antibiotic 
prescribing 
 Carling et al, Infect Control Hosp Epidemiol  2003. 
 Antimicrobial management team 
 Targeted 3rd gen cephalosporins and aztreonam 
 Stopped therapy after 2-3 days if no confirmed infection 
 Switched from IV to oral formulations 
 No impact on prevalence of VRE 
 No impact on prevalence of MRSA 
 Significant reduction in rate of CDI (P=.002) 
 Significant reduction in rate of antibiotic resistant GNRs 
Davy P et al. Cochran Database Syst Rev 2005.  
 
Fluoroquinolone resistant NAP1/BI/027 C. diff 
 Global emergence since highly publicized outbreaks in US 
and Canada in 2005. 
 More severe disease, higher 14 day mortality. 
 Two genetically distinct lineages 
 Identical mutation (Thr82Ile) in the DNA gyrase subunit A gene gyrA 
 High-level fluoroquinolone resistance 
 Possible control with fluoroquinolone restriction 
 
Nat Genet, 2013;45:109-13; Infect Control and Hosp Epidemiol, 2009;30:264-72. 
Kallen et al. Infect Control and Hosp Epidemiol, 2009;30:264-72. 
 
Figure 1.  Rate of hospital‐onset Clostridium difficile infection (CDI; dashed line), rate of 
hospital‐onset CDI predicted from an interrupted time‐series model (solid line), and percentage 
of C. difficile isolates recovered that were the epidemic strain (asterisks), January 2005‐March 
2007. A total of 61 isolates were tested during the outbreak period (June 2005‐May 2006); 33, 
during the FQ‐restriction period (June‐Oct 2006); and 24, during the FQ‐reinstitution period 
(Nov 2006‐Mar 2007). FQ, fluoroquinolone. 
2012 American Geriatrics Society Beers Criteria 
for Potentially Inappropriate Medication Use in 
Older Adults 
Anti-infective Rationale Recommendation Quality of Evidence Strength 
Nitrofurantoin 
Potential for 
pulmonary toxicity; 
safer alternatives 
available; lack of 
efficacy in patients 
with CrCl < 60 
mL/min due to 
inadequate drug 
concentration in the 
urine 
Avoid for long-
term suppression; 
avoid in patients 
with CrCl < 60 
mL/min 
Moderate Strong 
The American Geriatrics Society 2012 Beers Criteria Update Expert Panel (2012),  
Journal of the American Geriatrics Society, 60: 616–631. doi: 10.1111/j.1532-5415.2012.03923.x 
Ray WA et al. N Engl J Med 2012; 366:1881-1890: 10.1056/NEJMoa1003833 
Azithromycin and the risk of cardiovascular death 
2013 FDA warning 
 Consider the risk of torsades de pointes and fatal arrhythmia when 
prescribing azithromycin or alternative antibacterial drugs. Groups at 
higher risk include: 
 Patients with known prolongation of the QT interval, a history of torsades de pointes, 
congenital long QT syndrome, bradyarrhythmias, or uncompensated heart failure 
 Patients on drugs known to prolong the QT interval 
 Patients with hypokalemia or hypomagnesemia, clinically significant bradycardia, or 
receiving Class IA or Class III antiarrhythmic agents. 
 Elderly patients and patients with cardiac disease may be more susceptible to the 
effects of arrhythmogenic drugs on the QT interval. 
 The potential risk of QT prolongation should be placed in appropriate 
context when choosing an antibacterial drug: Alternative drugs in the 
macrolide or fluoroquinolone drug classes also have the potential for QT 
prolongation or other significant side effects that should be considered 
when choosing an antibacterial drug. 
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